|drug212||Anakinra and Ruxolitinib (overcome stage 3) Wiki||1.00|
|drug3146||Standard of care Wiki||0.19|
There is one clinical trial.
During SARS-Cov2 infection with serious respiratory implication and high systemic inflammation level, intravenous ANAKINRA alone or associated with RUXOLITINIB for severe cases might reduce inappropriate systemic inflammatory response, improve breathing and decrease occurrence or duration of ARDS and associated mortality.
Description: At least 3 parameters are met including CRP and/or Ferritin among: CRP: decrease > 50% Ferritinemia: decrease > 1/3 Serum creatinine: decrease > 1/3 AST/ALT: decrease > 50% Eosinophils > 50 /mm3 Lymphocytes > 1000 /mm3Measure: Biological criteria Time: 7 days from enrolment
Description: Number of days without mechanical ventilationMeasure: Duration of oxygen therapy (days) Time: 28 days from enrolment
Description: Number of patients included in stage 2bMeasure: Number of intensive care units admissions Time: 28 days from enrolment
Description: Number of days in intensive care units for patients managed in intensive care unitsMeasure: Number of days in intensive care units Time: 28 days from enrolment
Description: Mortality rateMeasure: Mortality rate Time: 28 days from enrolment
Description: Total number of days in hospitalMeasure: Total number of days in hospital Time: 28 days from enrolment
Description: Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score); Sofa score's minimum and maximum values are 0 and 24, the lowest score corresponds to a better outcome.Measure: Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score) Time: 28 days from enrolment
Description: Number of bacterial and/or fungal sepsisMeasure: Number of bacterial and/or fungal sepsis Time: 28 days from enrolment
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports